Improving Renal Protection in Chronic Kidney Disease Associated with Type 2 Diabetes: The Role of Finerenone

Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus(T2D), which often leads to diabetic kidney disease (DKD). Traditional therapies, including renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors, are effectivein slowing CKD progression. However, these approaches are insufficient to comprehensivelyinhibit mineralocorticoid receptor (MR) overactivation in the kidneys, which remains a significantdriver of inflammation, fibrosis, and oxidative stress. These pathological processes acceleratekidney damage and cardiovascular complications. Finerenone-a nonsteroidal mineralocorticoidreceptor antagonist-represents a new frontier in renal protection. Unlike steroidal mineralocorticoidantagonists (MRAs), finerenone offers a more selective MR blockade, reducing kidney inflammationand fibrosis without significantly raising serum potassium levels. Landmark trialshave demonstrated the ability of finerenone to significantly reduce kidney and cardiovascularevents in patients with T2D and CKD. Clinical evidence has highlighted finerenone as an effectiveoption for slowing DKD progression while maintaining a favorable safety profile. Based on thesefindings, recent guidelines have incorporated finerenone as a recommended therapy for patientswith T2D and CKD, emphasizing its role in reducing both renal and cardiovascular risks.This review provides a comprehensive overview of the available data to offer a deeper understandingof the potential of finerenone to transform CKD management for T2D patients.